This company has been acquired
Forma Therapeutics Holdings Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-53.2%
Tasa de crecimiento de los beneficios
40.8%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera | -45.9% |
| Margen neto | n/a |
| Última actualización de beneficios | 30 Jun 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30
Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11
Aug 05We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Mar 04We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Nov 20Here's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
Aug 13We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Needs To Drive Business Growth Carefully
Apr 18What Type Of Shareholders Own The Most Number of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Shares?
Jan 03Forma Therapeutics closes public offering priced at $45.25
Dec 16Forma Therapeutics prices equity offering at $45.25
Dec 11Forma Therapeutics' sickle cell treatment shows promising action at ASH presentation
Dec 08Forma Therapeutics EPS beats by $0.01
Nov 12Forma Therapeutics' sickle cell candidate an orphan drug in Europe
Nov 10Desglose de ingresos y gastos
Cómo gana y gasta dinero Forma Therapeutics Holdings. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -190 | 53 | 11 |
| 31 Mar 22 | 0 | -181 | 52 | 0 |
| 31 Dec 21 | 0 | -173 | 48 | 0 |
| 30 Sep 21 | 0 | -151 | 43 | 54 |
| 30 Jun 21 | 0 | -136 | 38 | 54 |
| 31 Mar 21 | 0 | -119 | 32 | 0 |
| 31 Dec 20 | 0 | -74 | 31 | 0 |
| 30 Sep 20 | 7 | -74 | 30 | 0 |
| 30 Jun 20 | 11 | -78 | 29 | 0 |
| 31 Mar 20 | 29 | -61 | 28 | 0 |
| 31 Dec 19 | 101 | -53 | 24 | 0 |
| 31 Dec 18 | 164 | 0 | 22 | 0 |
Ingresos de calidad: FMTX is currently unprofitable.
Margen de beneficios creciente: FMTX is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: FMTX is unprofitable, and losses have increased over the past 5 years at a rate of 53.2% per year.
Acelerando crecimiento: Unable to compare FMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: FMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Rentabilidad financiera
Alta ROE: FMTX has a negative Return on Equity (-45.88%), as it is currently unprofitable.